The benefit of using CT-perfusion imaging for reliable response monitoring in patients with gastrointestinal stromal tumor (GIST) undergoing treatment with novel targeted agents

Acta Radiologica

Volumn 54, Issue 7, 2013, Pages 711-721

  Betz, Martina ^a   Kopp, Hans Georg ^a   Spira, Daniel ^a   Claussen, Claus D ^a   Horger, Marius ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Gastrointestinal stromal tumor (GIST); Multitargeted tyrosine kinase inhibitors (TKI); Patterns of response; Volume perfusion CT(VPCT)

Indexed keywords

AMINO ACIDS; ENZYME INHIBITION; PATIENT TREATMENT; TUMORS;

CT PERFUSION; CT PERFUSION IMAGING; GASTROINTESTINAL STROMAL TUMORS; PATTERNS OF RESPONSE; PERFUSION MEASUREMENTS; PERFUSION-CT; SIGNALING PATHWAYS; TYROSINE KINASE INHIBITOR;

COMPUTERIZED TOMOGRAPHY;

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG ANTAGONISM; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL STROMAL TUMOR (GIST); GASTROINTESTINAL TUMOR; HUMAN; METHODOLOGY; MULTITARGETED TYROSINE KINASE INHIBITORS (TKI); PATTERNS OF RESPONSE; RADIOGRAPHY; REVIEW; THREE DIMENSIONAL IMAGING; VASCULARIZATION; VOLUME PERFUSION CT (VPCT);

GASTROINTESTINAL STROMAL TUMOR (GIST); MULTITARGETED TYROSINE KINASE INHIBITORS (TKI); PATTERNS OF RESPONSE; VOLUME PERFUSION CT (VPCT);

ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMAGING, THREE-DIMENSIONAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84886628524     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185113484642     Document Type: Review

References (34)

1. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN task force report: optimal management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw 2007;5:1-29.
2. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumor show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathol 1998;152:1259-69.
3. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumor. Lancet 2007;369:1731-41.
4. De Matteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51.
5. Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003;226:527-32.
6. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:71-83.
7. Judson I, Demetri G. Advanves in the treatment of gastrointestinal stromal tumour. Ann Oncol 2007;18:20-4.
8. Wong CS, Chu YC, Khong PL. Unusual features of gastrointestinal stromal tumor on PET/CT and CT imaging. Clin Nucl Med 2011;36:e1-7.
9. Pantaleo MA, Nannini M, Saponara M, et al.; GIST Study Group, University of Bologna, Bologna, Italy. Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours. Anticancer Drugs 2012;23:567-72.
10. Dudeck O, Zeile M, Reichardt P, et al. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol 2011;22:1828-33.
11. Rossi F, Yozgat Y, de Stanchina E, et al. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res 2010;8:1271-83.
12. De Giorgi U, Aliberti C, Benea G, et al. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2005;11:6171-6.
13. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomographie and positron emission tomographie in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tompgraphie response criteria. J Clin Oncol 2007;25:1753-9.
14. Stacchiotti S, Collini P, Messina A, et al. High-grade soft-tissue sarcomas: Tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009;251:447-56.
15. Petralia G, Preda L, D'Andrea G, et al. CT perfusion in solid-body tumours. Part I: Technical issues. Radiol Med 2010;115:843-57.
16. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003;76:S36-42.
17. Miles KA, Charnsangavej C, Lee FT, et al. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000;7:840-50.
18. Kambadakone AR, Sahani DV. Body perfusion CT: Technique, clinical applications, and advances. Radiol Clin North Am 2009;47: 161-78.
19. Sauter AW, Merkle A, Schulze M, et al. Intraobserver and interobserver agreement of volume perfusion CT (VPCT) measurements in patients with lung lesions. Eur J Radiol 2012;81:2853-9.
20. Hayano K, Shuto K, Koda K, et al. Quantitative measurement of blood flow using perfusion CT for assessing clinicopathologic features and prognosis in patients with rectal cancer. Dis Colon Rectum 2009;52:1624-9.
21. Goh V, Halligan S, Wellsted DM, et al. Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol 2009;19:79-89.
22. Petralia G, Bonello L, Viotti S, et al. CT perfusion in oncology: how to do it. Cancer Imaging 2010;10:8-19.
23. Hermans R, Meijerink M, Van den BogaertW, et al. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1351-6.
24. Fournier LS, Oudard S, Thiam R, et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010;256:511-8.
25. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol 2006;187:1267-73.
26. Antoch G, Kania J, Bauer S, et al. Comparison of PET, CT and dual-modality PET/CT imaging for monitoring of imatinib (STI-%/!) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357-65.
27. Schlemmer M, Sourbron SP, Schinwald N, et al. Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. Eur J Rad 2011;77:312-18.
28. Huynh H, Lee JW, Chow PK, et al. Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther 2009;8:152-9.
29. Reichardt P, Schneider U, Stroszczynski C, et al. Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol 2004;57:215-7.
30. Izawa N, Sawada T, Abiko R, et al. Gastrointestinal stromal tumor presenting with prominent calcification. World J Gastroenterol 2012;18:5645-8.
31. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011;37:75-88.
32. Lassau N, Chami L, Chebil M, et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med 2011;11:18-24.
33. Shankar S, vanSonnenberg E, Desai J, et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005;235:892-8.
34. Ryu MH, Lee JL, Chang HM, et al. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol 2006;36:17-24.